Guselkumab in psoriatic arthritis found to be Efficient: Stu
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
In two phase 3 trials, the efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic arthritis (PsA) was recently demonstrated and found to be successful. Via network meta-analysis (NMA), the aim was to compare guselkumab to targeted therapies for PsA in terms of protection and joint and skin efficacy.

A systematic literature review was conducted to identify randomized controlled trials. Bayesian NMAs were performed to compare treatments on American College of Rheumatology (ACR) 20/50/70 response, mean change from baseline in van der Heijde-Sharp (vdH-S) score, Psoriasis Area Severity Index (PASI) 75/90/100 response, adverse events (AEs) and serious adverse events (SAEs).

--26 phase 3 studies evaluating 13 targeted therapies for PsA were included.

--For ACR 20 response, guselkumab 100?mg every 8?weeks (Q8W) was comparable to IL-17A inhibitors and subcutaneous tumor necrosis factor (TNF) inhibitors.

--Similar findings were observed for ACR 50 and 70. For vdH-S score, guselkumab Q8W was comparable to other agents except intravenous TNF therapies.

--Results for PASI 75 and PASI 90 response suggested guselkumab Q8W was better than most other agents.

--For PASI 100, guselkumab Q8W was comparable to other active agents.

--For AEs and SAEs, guselkumab Q8W ranked highly but comparative conclusions were uncertain. Similar results were observed for all outcomes for guselkumab 100?mg every four weeks.

Finally, guselkumab showed favorable arthritis efficacy in this NMA, comparable to IL-17A and subcutaneous TNF inhibitors, thus providing a stronger PASI response than many other therapies.